Liver biopsy performance and histological findings among patients with chronic viral hepatitis: A Danish database study

Christensen, Peer Brehm; Krarup, Henrik; Møller, Axel; Laursen, Alex Lund; Kjær, Mette; Orholm, Marianne; Lindberg, Jens; Groenbaek, Karin; Kromann-Andersen, H; Weis, Nina

doi:10.1080/00365540600978864

Cited by 12 publications

(11 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such association would support the knowledge that increasing time of exposure increases the risk of developing cirrhosis and increases the level of neutralizing antibodies [25], [33], [53], [54]. Surprisingly, we found a significant association between the NAb 50 -titers against two viruses, TN/JFH1 and DH5/JFH1 and the BMI of the patients, which has to our knowledge not previously been shown in patients with chronic HCV infection.…”

Section: Discussionsupporting

confidence: 88%

Neutralizing Antibodies in Patients with Chronic Hepatitis C, Genotype 1, against a Panel of Genotype 1 Culture Viruses: Lack of Correlation to Treatment Outcome

et al. 2013

Self Cite

View full text Add to dashboard Cite

The correlation of neutralizing antibodies to treatment outcome in patients with chronic hepatitis C virus (HCV) infection has not been established. The aim of this study was to determine whether neutralizing antibodies could be used as an outcome predictor in patients with chronic HCV, genotype 1, infection treated with pegylated interferon-α and ribavirin. Thirty-nine patients with chronic hepatitis C, genotype 1a or 1b, with either sustained virologic response (n = 23) or non-sustained virologic response (n = 16) were enrolled. Samples taken prior to treatment were tested for their ability to neutralize 6 different HCV genotype 1 cell culture recombinants (1a: H77/JFH1, TN/JFH1, DH6/JFH1; 1b: J4/JFH1, DH1/JFH1, DH5/JFH1). The results were expressed as the highest dilution yielding 50% neutralization (NAb50-titer). We observed no genotype or subtype specific differences in NAb50-titers between patients with chronic HCV infection with and without sustained virologic response when tested against any of the included culture viruses. However, NAb50-titers varied significantly with a mean reciprocal NAb50-titer of 800 (range: 100–6400) against DH6/JFH1 compared to a mean NAb50-titer of 50 (range: <50–400) against all other included isolates. Subsequent studies demonstrated that the efficient neutralization of DH6/JFH1 could be linked to engineered adaptive mutations in the envelope-2 protein. In analysis of envelope 1 and 2 sequences of HCV, recovered from a subset of patients, we observed no apparent link between relatedness of patient sequences with culture viruses used and the corresponding neutralization results. In conclusion, pre-treatment levels of neutralizing antibodies against HCV genotype 1 isolates could not predict treatment outcome in patients with chronic HCV infection. High neutralization susceptibility of DH6/JFH1 could be correlated with adaptive envelope mutations previously highlighted as important for neutralization. Our study emphasizes the importance of using multiple culture viruses for neutralization studies and contributes to the current knowledge about neutralizing epitopes, important for future therapeutic- and vaccine-studies.

show abstract

Section: Discussionsupporting

confidence: 88%

Neutralizing Antibodies in Patients with Chronic Hepatitis C, Genotype 1, against a Panel of Genotype 1 Culture Viruses: Lack of Correlation to Treatment Outcome

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…Denmark has a population of 5.4 million,17 with an estimated HCV prevalence of 0.3% 18. HCV‐infected patients are treated in hospital departments that are specialized in infectious diseases, gastroenterology or hepatology 19. Medical care, including antiviral treatment, is provided free‐of‐charge to all HCV‐infected residents.…”

Section: Methodsmentioning

confidence: 99%

Medullary thyroid microcarcinoma

Kazaure

Roman

Sosa

2011

Cancer

View full text Add to dashboard Cite

BACKGROUND: Medullary thyroid microcarcinomas (microMTCs) are medullary thyroid carcinomas (MTCs) that measure 1 cm in size for which there is a paucity of data on incidence, characteristics, and clinical significance. METHODS: Patients who had a diagnosis of microMTC were abstracted from the Surveillance, Epidemiology, and End Results database (1988)(1989)(1990)(1991)(1992)(1993)(1994)(1995)(1996)(1997)(1998)(1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007). The data were analyzed using chi-square tests, t tests, and log-rank tests; multivariate logistic regression was used to identify factors that were associated independently with lymph node metastases. Tests for diagnostic accuracy, including likelihood ratio tests and post-test probability tests, were computed to evaluate the size-specific likelihood of developing lymph node metastases among patients with microMTC. RESULTS: In total, 310 patients had microMTC; its incidence increased during the study period (P trend ¼ .033), and microMTC as a proportion of all MTCs increased by 39%. The mean tumor size was 5.7 mm. Thirty-one percent of tumors were multifocal, and 7.8% had extrathyroid extension. Lymph node metastases occurred in nearly 37% of patients who had any lymph nodes removed (65 of 176 patients). Nearly 20% of patients had regional disease, and 5% had distant metastases. The overall 10-year survival rates for patients with localized, regional, and distant disease stages were 96%, 87%, and 50%, respectively (P < .001). After adjustment, extrathyroid extension (odds ratio [OR], 41.9; P < .001) and tumor size (OR, 1.2; P ¼ .008) retained an independent association with lymph node metastases. MTCs that measured 5 mm were associated with a probability of lymph node metastases of approximately 23%, and the probability increased for patients who had tumors >5 mm. CONCLUSIONS: The current results indicated that microMTCs have significant rates of poor prognostic features known to impact the survival of patients with MTC. These microcarcinomas are an important clinical entity that requires comprehensive evaluation and surgical management. Cancer 2012;118:620-

show abstract

“…Treatment of HCV-infected patients takes place in hospital departments specialised in infectious diseases, gastroenterology or hepatology [10]. Although medical care, including antiviral treatment, is provided free-of-charge to all HCV-infected residents of Denmark, only 2% of the Danish HCV-infected population has been treated with interferon [11].…”

Section: Settingmentioning

confidence: 99%

Mortality in patients with chronic and cleared hepatitis C viral infection: A nationwide cohort study

Omland

Krarup

Jepsen

et al. 2010

Journal of Hepatology

View full text Add to dashboard Cite

Liver biopsy performance and histological findings among patients with chronic viral hepatitis: A Danish database study

Cited by 12 publications

References 18 publications

Neutralizing Antibodies in Patients with Chronic Hepatitis C, Genotype 1, against a Panel of Genotype 1 Culture Viruses: Lack of Correlation to Treatment Outcome

Neutralizing Antibodies in Patients with Chronic Hepatitis C, Genotype 1, against a Panel of Genotype 1 Culture Viruses: Lack of Correlation to Treatment Outcome

Medullary thyroid microcarcinoma

Mortality in patients with chronic and cleared hepatitis C viral infection: A nationwide cohort study

Contact Info

Product

Resources

About